Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Bepotastine Experts for Allergic Conjunctivitis.: Opthalmologists

Council Members in this Study Group: 20

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Barry Schechter, Director of Corneal and External Diseases, FLORIDA EYE MICROSURGICAL INSTITUTE INCBarry Schechter

Director of Corneal and External Diseases
FLORIDA EYE MICROSURGICAL INSTITUTE INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Barry Schechter, MD, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Dr. Schechter's practice involves diseases of the ocular surface including dry eyes, allergies, infection; the latest in corneal,...

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Bausch makes foray into presbyopic arena

January 29, 2008

Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com

With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.

Newly identified risks for refractive surgery

April 16, 2007

Researchers report 13 cases of MRSA keratitis after laser refractive surgery | www.osnsupersite.com

Refractive surgery is taken for granted by patients to "get rid of their glasses and contact lenses". They rarely consider the possibility of loss of vision.

ISTA takes the lead in topical NSAID therapy

February 14, 2007

ISTA Pharmaceuticals Announces Positive Preliminary Xibrom Once-daily Formulation Clinical Results From U.S. Phase III Trials | pharmalive.com

There has been a sea change in the treatment of postoperative cataract patients. The addition of a nonsteroidal has significantly reduced postoperative complications such as edema, discomfort and inflammation.

Compliance with all medications is always an issue, and the use of a once daily medication potentially makes this a non-issue. I have been impressed with the BID Xibrom and my patients in the phase 3 trial did exceptionally well.

I expect that this will be well received, pending acceptance of formularies.

Additional Thoughts on Fusarium

May 10, 2006

Doubt Cast on Early Theory on Eye Infections | www.nytimes.com

Multiple species of Fusarium have been reported as pathogens.

ReStor gradually becoming more popular

May 10, 2006

Alcon Still Not Living Up to Valuation | www.fool.com

Dr Packer writes that the ReStor lens is taking time to catch on with cataract surgeons.

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Other Freestanding Healthcare Facility
  • Non-Academic Community Hospital or Clinic

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • President
  • Partner
  • Owner
  • Chief Executive Officer
  • Medical Director
  • Physician - Division Head